HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Johnson, K. P. Search for Related Content PubMed PubMed Citation Articles by Johnson, K. P.

Cerebrospinal fluid and blood assays of diagnostic usefulness in multiple sclerosis

Neurology Service, Veterans Administration Medical Center and the University of California, San Francisco, CA.

Address correspondence and reprint requests to Dr. Johnson, Veterans Administration Medical Center, Neurology (127), 4150 Clement Street, San Francisco, CA 94121.

Although the ultimate diagnosis of multiple sclerosis (MS) still remains clinical, confirmatory laboratory aids can be of marked assistance, especially in early and atypical cases. Whereas numerous tests have been described, the only ones to withstand scrutiny in numerous laboratories have been various immunoglobulin assays and myelin basic protein measurements in the cerebrospinal fluid (CSF). Of the newer assays that are commercially available and readily adapted to routine clinical laboratory use, the most discriminating are the production of a CSF IgG:albumin ratio, using an electroimmunodiffusion method, and agarose electrophoresis of concentrated CSF to demonstrate oligoclonal IgG bands. Together, these assays can be performed on less than 3 ml of CSF, and will show relatively specific abnormalities in over 95% of clinically definite MS patients. They both detect abnormalities that frequently occur in the course of disease, and thus add considerable weight to the clinical impression of MS.

Accepted for publication September 16, 1979.

Supported by the research service of the Veterans Administration, grant No. RG 1224 from the National Multiple Sclerosis Society, and grant No. NS 14069 from the USPHS.